Invivyd (IVVD) Interest Expenses (2020 - 2025)
Invivyd (IVVD) posted Interest Expenses of -$315000.0 for Q4 2025, down 138.27% on a QoQ basis from $823000.0 in Q3 2025, and up 55.26% year-over-year from -$202891.1 in Q4 2024.
Invivyd (IVVD) Interest Expenses (2020 - 2025) Analysis & Trends
Invivyd's Interest Expenses history runs 6 years deep, the most recent figure standing at -$315000.0 for Q4 2025.
- Quarterly Interest Expenses rose 55.26% year-over-year to -$315000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$459000.0 (down 39.09% YoY) and the FY2025 annual result came in at $252.2 million, up 3.18% from the prior year.
- Interest Expenses was -$315000.0 for Q4 2025 at Invivyd, down from $823000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $586.8 million in Q3 2021 and bottomed at -$704000.0 in Q4 2024.
- A 5-year average of $36.3 million and a median of $435000.0 in 2024 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses soared 10494.0% — and 2023, when it slumped 348.0%.
- Invivyd's Interest Expenses stood at $200000.0 in 2021, then changed by 0.0% to $200000.0 in 2022, then tumbled by 348.0% to -$496000.0 in 2023, then tumbled by 41.94% to -$704000.0 in 2024, then soared by 55.26% to -$315000.0 in 2025.
- Business Quant data shows IVVD's Interest Expenses at -$315000.0 in Q4 2025, $823000.0 in Q3 2025, and $360000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Invivyd | 104.48 Mn | -122.21 Mn | 16.07 Mn | -315,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -315,000.00 |
| Dec 31, 2025 | -315,000.00 |
| Sep 30, 2025 | 823,000.00 |
| Sep 30, 2025 | 823,000.00 |
| Jun 30, 2025 | 360,000.00 |
| Jun 30, 2025 | 360,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | -704,000.00 |
| Dec 31, 2024 | -704,000.00 |
| Sep 30, 2024 | 435,000.00 |
| Sep 30, 2024 | 435,000.00 |
| Jun 30, 2024 | 435,000.00 |
| Jun 30, 2024 | 435,000.00 |
| Mar 31, 2024 | 33.25 Mn |
| Mar 31, 2024 | 33.25 Mn |
| Dec 31, 2023 | -496,000.00 |
| Dec 31, 2023 | -496,000.00 |
| Sep 30, 2023 | 1.98 Mn |
| Sep 30, 2023 | 1.98 Mn |